The Brigham and Women's Hospital, Inc.

Harvard College

The General Hospital Corporation

National Research Council of Canada

California Institute of Technology

Duke University

Children's Medical Center Corporation

The Bingham and Women's Hospital

The General Hospital Corporation & Brigham and Women's Hospital

Dennis L Kasper

Lawrence C Madoff

James L Michel

Frederick M Ausubel

Arthur O Tzianabos

Harold J Jennings

Andrew B Onderdonk

Ying Wang

Sarkis K Mazmanian

Laurie E Comstock

Michael J Coyne

Katja G Weinacht

Sungwhan Oh

Deniz Erturk-Hasdemir

Rawle I Hollingsworth

Julia Y Wang

Michael H Roehrl

Donald Elliot Ingber

Francis Michon

Richard S Blumberg

Richard Novak

Ryan Michael O'Connell

Robert L Deresiewicz

Vince Pozsgay

June L Round

Fikri Avci

Robert J Chalifour

Robert W Finberg

Robert Feldman

Martial Lacroix

Dingding An

Hilde-Kari Guttormsen

Nancy J Levy

Michael R Wessels

Elizabeth L Calamari

Bret A Nestor

Francesca S Gazzaniga

Michael L Cronce

Torsten Olszak

Sasan Jalili-Firoozinezhad

Diogo M Camacho

Joana F Neves

Cicely Fadel

Amir Bein

Neeraj K Surana

Kailyn L Stefan

Barbara Reinap

Sung-Eun Lee

Dori F Zaleznik

Joana Pereira Das Neves

In certain aspects, described herein are methods, bacteria, and compositions for the treatment of bacterial infections. Specifically, bacteria that can upregulate antimicrobial peptides, e.g., Reg3, within a subject have been identified and methods of using such bacteria to treat infections is described.

Methods and compositions to treat and prevent infection

A microfluidic device is directed to sustaining a complex microbial community in direct and indirect contact with living human intestinal cells in vitro. The device includes a first microchannel having cultured cells of a human intestinal epithelium and microbiota, the first microchannel further having a first level of oxygen. The device further includes a second microchannel having cultured cells of a vascular endothelium, the second microchannel further having a second level of oxygen. The device also includes a membrane located at an interface region between the first microchannel and the second microchannel, the membrane being composed of an oxygen-permeable material or further having pores via which oxygen flows between the first microchannel and the second microchannel to form a physiologically-relevant oxygen gradient.

Complex human gut microbiome cultured in an anaerobic human gut-on-a-chip

Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.

Immunomodulating compounds and related compositions and methods

The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.

Glycolipid compositions and methods of use

The invention provides various isolated and synthetic forms of lipidated PSA as well as isolated or synthetic forms of the glycolipid component of lipidated PSA, and compositions thereof, methods of making including methods of isolating such forms, and methods of use thereof.

Lipidated PSA compositions and methods

The invention provides, inter alia, immunoinhibitory glycosphingolipids and immunoinhibitory alpha-galactosylceramides and compositions and preparations thereof, and methods of use thereof including in the treatment of conditions characterized by increased iNKT cells and/or activity.

Glycosphingolipids and methods of use thereof

The invention provides compositions comprising lipid-conjugated forms of capsular polysaccharide A (PSA) from(referred to herein as PSA-LT), methods of isolating such forms and of making such compositions and methods for their use.

Lipid-containing PSA compositions, methods of isolation and methods of use thereof

Glycoconjugate vaccines and methods of preparing and using the same are described.

Glycoconjugate vaccines

Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo.

Zwitterionic immunomodulators for the treatment of asthma and allergy

Provided is an isolatedbacterial cell producing a native capsular polysaccharide A (PSA), wherein the cell is incapable of producing capsular polysaccharides PSB, PSC, PSD, PSE, PSF, PSG, and PSH because the cell's biosynthetic genes for native capsular polysaccharides PSB, PSC, PSD, PSE, PSF, PSG, and PSH have been deleted from the cell's genome. The isolated or wild typecell, or an extract obtained from saidcell, can be used to treat individuals with inflammation.

[object Object]

Certain zwitterionic polysaccharides, including those naturally expressed by commensalin the gut, interact with cells of the immune system and affect the T1/T2 balance so as to promote health. Nutritional formulas and nutritional supplements containing isolated preparations of such zwitterionic polysaccharides, and methods for preparing the nutritional formulas and supplements, are provided. Also provided is a method of promoting immune system maturation in an infant involving enteral administration of a nutritional formula or nutritional supplement of the invention.

Zwitterionic polysaccharides for promotion of immune system maturation and health

The invention relates to three-dimensional molecular structure determination of polymers, three-dimensional computer molecular modeling, rational drug design, and immunomodulatory polymers. In particular the invention is directed to immunomodulatory polymers, as well as to methods for designing, selecting, and screening therapeutic agents having immunomodulatory activity.

Use of zwitterionic polysaccharides for the specific modulation of immune processes

Modified streptococcal polysaccharides and methods of using the modified polysaccharides are provided herein.

Modified streptococcal polysaccharides and uses thereof

The present invention is directed to methods for producing and selecting new mutant strains ofthat constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; compositions directed to the new mutant strains ofthat constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; improved methods for purification of individual capsular polysaccharides; and compositions directed to new res02 and inv19 genes and their gene products. Significantly, the present invention provides methods and compositions for overexpressing and purifying immunomodulatory capsular polysaccharide A (PSA) in high yield.

Method for overexpression of zwitterionic polysaccharides

The present invention is directed to methods for producing and selecting novel mutant strains ofthat constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; compositions directed to the novel mutant strains ofthat constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; improved methods for purification of individual capsular polysaccharides; and compositions directed to novel res02 and inv19 genes and their gene products. Significantly, the present invention provides methods and compositions for overexpressing and purifying immunomodulatory capsular polysaccharide A (PSA) in high yield.

Growing community of inventors

Brookline, MA, United States of America

Dennis L Kasper